Serodus ASA Share Price

Stocks

03/01/17	Serodus : Primary endpoint reached by SER150 Phase 2a study in Diabetic Nephropathy.	PU
08/12/16	Serodus : Q&A delisting from Oslo Axess	PU
23/11/16	Serodus : Extraordinary general meeting held	PU
23/11/16	Serodus : Viggo Harboe Holding 2006 ApS announces results of voluntary offer	PU
02/11/16	Serodus : Viggo Harboe Holding 2006 Aps Launces voluntary offer for outstanding shares in Serodus ASA – Acceptance period starting 31 October 2016	PU

1 day

-5.56%

Manager	Title	Age	Since
Arnstein Gunnestad Endresen CEO	Chief Executive Officer	73	31/12/2022
Henrik Mordhorst DFI	Director of Finance/CFO	-	30/09/2019
Daniel Capion PRN	Corporate Officer/Principal	-	31/12/2020

Director	Title	Age	Since
Søren Elmann Ingerslev CHM	Chairman	-	31/12/2016
Terri Sebree BRD	Director/Board Member	68	31/03/2014
Viggo Gunnersen Harboe BRD	Director/Board Member	80	31/12/2021

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
SERODUS ASA	-5.56%	+7.94%	-	-	0
WUXI APPTEC CO., LTD.	-0.31%	+5.79%	+47.13%	+99.00%	70.88B
ARGENX SE	+0.39%	+2.06%	+39.38%	+78.27%	62.49B
WUXI BIOLOGICS (CAYMAN) INC.	+0.50%	+7.13%	+33.27%	+16.01%	26.34B
INSMED INCORPORATED	-3.21%	-7.27%	-17.10%	+356.10%	26.21B
BIONTECH SE	-2.64%	-0.69%	-0.17%	-13.01%	24.13B
GENMAB A/S	+0.71%	+8.03%	+25.03%	-12.74%	20.72B
PHARMAESSENTIA CORPORATION	+2.12%	-5.86%	+161.58%	+329.34%	15.36B
EXELIXIS, INC.	-0.22%	+3.99%	+45.54%	+172.46%	14.46B
SUMMIT THERAPEUTICS INC.	+0.73%	+1.71%	-5.51%	+849.47%	14.24B
Average	-0.75%	+1.74%	+36.57%	+208.32%	30.54B
Weighted average by Cap.	-0.28%	+1.49%	+35.68%	+148.22%

Employees

Sector